Francisco Trust Under Agreemen Sells 41,143 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 41,143 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $1.84, for a total value of $75,703.12. Following the sale, the insider owned 3,455,764 shares in the company, valued at $6,358,605.76. The trade was a 1.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

NASDAQ DYAI opened at $0.94 on Monday. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a fifty day moving average of $0.77 and a two-hundred day moving average of $0.83. The firm has a market capitalization of $34.27 million, a price-to-earnings ratio of -4.09 and a beta of 1.15. Dyadic International Inc. has a 52 week low of $0.65 and a 52 week high of $1.35.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Dyadic International

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the period. Marathon Capital Management purchased a new stake in shares of Dyadic International during the third quarter valued at $41,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International during the third quarter valued at $190,000. Geode Capital Management LLC grew its holdings in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the last quarter. Finally, Apis Capital Advisors LLC bought a new position in shares of Dyadic International in the third quarter worth about $1,817,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.